Craft

Merck Summary

Overview

Merck & Co (also known as Merck Sharp & Dohme) is a healthcare manufacturer and distributor of pharmaceuticals. The company operates through two segments: Pharmaceutical and Animal Health. The Pharmaceutical segment includes human health pharmaceutical and vaccine products that consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies, and managed health care providers. The Animal Health segment discovers, develops, manufactures, and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment, and control of disease in major livestock and companion animal species.
TypePublic
Founded1891
HQKenilworth, NJ, USMap
Websitemerck.com
Employee Ratings
4.1
More
Overall CultureA-More

Locations

Merck is headquartered in
Kenilworth, United States

Location Map

Latest Updates

Company Growth (employees)

Employees (est.) (Dec 2021)67,000(-8%)
Job Openings3,412
Website Visits (Jan 2022)1 m(+15%)
Revenue (FY, 2021)$48.7 B(+1%)
Share Price (Apr 2022)$84.4
Cybersecurity ratingAMore
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner

Key People/Management at Merck

Merck Office Locations

Merck has offices in Kenilworth, Albuquerque, Alexandria, Allen and in 235 other locations

Merck Financials and Metrics

Merck Revenue

Merck's revenue was reported to be $48.7 b in FY, 2021

USD

Revenue (FY, 2021)$48.7 b
Gross profit (FY, 2021)$35.08 b
Gross profit margin (FY, 2021), %72.0%
Net income (FY, 2021)$13.05 b
Market capitalization (27-Apr-2022)$213.21 b
Closing stock price(27-Apr-2022)$84.41
Cash (31-Dec-2021)$8.1 b
EV $238.22 b

Merck's current market capitalization is $213.2 b.

USDFY, 2019FY, 2020FY, 2021
Revenue46.8 b48 b48.7 b
Revenue growth, %11%2%
Cost of goods sold14.1 b15.5 b13.6 b
Gross profit32.7 b32.5 b35.1 b
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021
Revenue10.8 b11.8 b12.4 b12.1 b10.9 b12.6 b12.1 b11.4 b13.2 b
Cost of goods sold3.1 b3.4 b4 b3.3 b3.2 b3.5 b3.7 b3.1 b3.5 b
Gross profit7.8 b8.4 b8.4 b8.7 b7.7 b9.1 b8.4 b8.3 b9.7 b
Gross profit Margin, %72%71%68%73%71%72%70%73%74%
show all

USDFY, 2019FY, 2020FY, 2021FY, 2021
Cash9.7 b8.1 b10 b8.1 b
Accounts Receivable6.8 b7.9 b8.6 b9.2 b
Inventories6 b6.3 b5.6 b6 b
Current Assets27.5 b27.8 b31.1 b30.3 b
show all

USDFY, 2019FY, 2020FY, 2021
Net Income9.8 b7.1 b12.4 b
Depreciation and Amortization3.7 b3.6 b3.2 b
Accounts Receivable294 m(1 b)
Inventories(508 m)(855 m)
USDQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021
Net Income2.9 b5.5 b7.4 b3.2 b6.2 b9.2 b3.2 b4 b8.5 b
Depreciation and Amortization898 m1.9 b2.7 b821 m1.9 b2.7 b930 m1.6 b2.4 b
Cash From Operating Activities1.3 b4.4 b8.6 b707 m4.1 b6.2 b1.8 b3.2 b8 b
Capital Expenditures(595 m)(1.4 b)(2.3 b)(986 m)(1.7 b)(3.2 b)(1.1 b)(2.1 b)(3.2 b)
show all

USD
FY, 2021
EV/CFO16.8 x
EV/FCF25.3 x
Revenue/Employee726.9 k
Debt/Equity0.9 x
Debt/Assets0.3 x
Financial Leverage2.8 x
P/E Ratio14.9 x
  • Merck Market Cap History

  • Merck Stock Price

Revenue Breakdown

Merck revenue breakdown by business segment: 87.8% from Pharmaceutical, 11.4% from Animal Health and 0.8% from Other

Merck revenue breakdown by geographic segment: 27.4% from Europe, Middle East and Africa, 5.6% from Japan, 46.0% from United States, 9.0% from China and 12.0% from Other

Merck Operating Metrics

Merck's Patent Portfolios was reported to be 25 in FY, 2020.

FY, 2018FY, 2019Apr, 2020Aug, 2020Nov, 2020FY, 2020
Phase III Trials Products172424242524
Phase II Trials Products141919193237
Products9893102
Patent Applications (US)11

Merck Acquisitions / Subsidiaries

Company NameDateDeal Size
Acceleron PharmaSeptember 30, 2021
Pandion TherapeuticsFebruary 25, 2021
OncoImmuneNovember 23, 2020$425 m
VelosBioNovember 06, 2020$2.75 b
Themis BioscienceMay 26, 2020
ArQuleDecember 09, 2019$2.7 b
Calporta Therapeutics, Inc.November 13, 2019$576 m
Tilos TherapeuticsJune 10, 2019$773 m
Peloton TherapeuticsMay 21, 2019$2.25 b
ConnectMedApril 05, 2019

Human Capital Metrics

Source: msd20-assets.s3.amazonaws.com

Merck Hiring Categories

Merck Median Salaries

Source: 8 public H-1B filings from Merck

Merck Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Merck Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Merck Website Traffic

Total Visits per monthSimilarWeb

Merck Online and Social Media Presence

Twitter followers

221.6 k Twitter followers

6 Months

Merck has 221.6 k Twitter Followers. The number of followers has increased 0.06% month over month and increased 0.51% quarter over quarter.

Merck's Trends

Search term - Merck

Twitter Engagement Stats for @merck

  • 9.17 k

    Tweets

  • 1.01 k

    Following

  • 221.6 k

    Followers

  • 27

    Tweets last 30 days

  • 13.4

    Avg. likes per Tweet

  • 100%

    Tweets with engagement

Merck Technology StackBuildWith Logo

  • ads

    25 products used

    • Advertising.com
    • Aggregate Knowledge
    • AppNexus
      • AppNexus Segment Pixel
      • BlueKai
      • BlueKai DMP
      • DoubleClick.Net
      • Drawbridge
      • Dstillery
      • ExactTarget
      • eXelate
      • Eyeota
      • Facebook Custom Audiences
      • Facebook Exchange FBX
      • Google Remarketing
      • IntentIQ
      • LinkedIn Ads
      • LiveIntent
      • Neustar AdAdvisor
      • Resonate Insights
      • Rocket Fuel
      • Tapad
      • The Trade Desk
      • Turn
      • Twitter Ads
  • analytics

    36 products used

    • Agora
    • Akamai mPulse
    • AudioEye
      • Azure Monitor
      • comScore
      • Cross Pixel Media
      • Datalogix
      • DoubleClick Floodlight
      • Dynatrace
      • Facebook Conversion Tracking
      • Facebook Domain Insights
      • Facebook Pixel
      • Facebook Signal
      • Global Site Tag
      • Google Analytics
      • Google Analytics Classic
      • Google Analytics IP Anonymization
      • Google Conversion Linker
      • Google Universal Analytics
      • Hotjar
      • LinkedIn Insights
      • LiveRamp
      • Lotame Crowd Control
      • MediaMath
      • Microsoft Azure Monitor
      • New Relic
      • Omniture SiteCatalyst
      • OwnerIQ
      • Rapleaf
      • Signal
      • Tealium UTAG
      • Twitter Conversion Tracking
      • Twitter Website Universal Tag
      • Usablenet
      • WebTrends
      • Zeotap
  • CDN

    20 products used

    • AJAX Libraries API
    • Akamai
    • Akamai Global Host
      • Amazon S3
      • BootstrapCDN
      • CDN JS
      • Cloudflare
      • Cloudflare JS
      • CloudFront
      • Content Delivery Network
      • Facebook CDN
      • GStatic Google Static Content
      • jQuery CDN
      • jsDelivr
      • Limelight Networks
      • OSS CDN
      • Twitter CDN
      • UNPKG
      • WordPress Grid
      • Zencoder CDN
  • cdns

    3 products used

    • Akamai Edge
    • Amazon CloudFront
    • Amazon S3 CDN
Learn more on BuiltWith

Merck Company CultureCultureAndCompensation Logo

  • Overall Culture

    A-

    74/100

  • CEO Rating

    A-

    76/100

  • Compensation

    B+

    75/100

  • Diversity

    A-

    77/100

Learn more on Comparably

Merck News and Updates

May 02, 2022
Thinking about trading options or stock in Merck, Tesla, Netflix, Advanced Micro Devices, or Bank of America?
NEW YORK, May 2, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRK, TSLA, NFLX, AMD, and BAC. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...
Apr 29, 2022
Biocytogen Enters into Antibody Agreement with Merck KGaA, Darmstadt, Germany
BEIJING, April 29, 2022 /PRNewswire/ -- Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen) announced that it has entered into an evaluation and option agreement with Merck KGaA, Darmstadt, Germany to grant them a sole license to evaluate Biocytogen's proprietary antibodies...
Apr 28, 2022
Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth
_3xOCqMerck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.
Apr 28, 2022
Merck reports COVID antiviral sales top $3 billion
_3xOCqMerck reports COVID antiviral sales top $3 billion
Apr 28, 2022
Merck shares pop premarket after earnings beat as COVID antiviral sales top $3 billion
_3xOCqMerck & Co. Inc. shares rose 1.9% in premarket trade Thursday, after the drug company topped estimates for the first quarter, buoyed by more than $3 billion in sales of its COVID-19 antiviral. The company posted net income of $4.310 billion, or $1.70 a share, for the quarter, up from $2.745 billion, or $1.08 a share, in the year-earlier period. Adjusted per-share earnings came to $2.14, ahead of the $1.83 FactSet consensus. Sales rose 50% to $15.901 billion from $10.627 billion, also ahead of the $14.556 billion FactSet consensus. Sales of Lagevrio, the brand name for Merck's COVID-19 antiviral molnupiravir, came to $3.2 billion. Excluding those, sales grew 19%. Sales of cancer drug Keytruda rose 23% to $4.8 billion, while sales of HPV vaccine Gardasil and Gardasil 9 grew 59% to $1.5 billion. Merck is expecting full-year sales of $56.9 billion to $58.1 billion, compared with a FactSet consensus of $57.2 billion. It expects adjusted EPS of $7.24 to $7.36, compared with a FactSet consensus of $7.28. Shares have gained 10% in the year to date, while the Dow Jones Industrial Average has fallen 8%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Apr 28, 2022
Merck Profit Boosted by Sales of Covid-19 Pill
_3xOCqMerck Profit Boosted by Sales of Covid-19 Pill

Merck Blogs

May 28, 2020
Merck’s KEYTRUDA® (pembrolizumab) Superior to Standard of Care Chemotherapy in Patients with MSI-H Colorectal Cancer
Dateline City: KENILWORTH, N.J. KEYTRUDA Monotherapy Significantly Reduced Risk of Disease Progression or Death by 40% and More Than Doubled Median Progression-Free Survival Versus Chemotherapy KEYNOTE-177 is the First Positive Head-to-Head Phase 3 Trial of a Single-Agent, Anti-PD-1 Therapy Compared to Chemotherapy as First-Line Treatment for Patients with MSI-H Colorectal Cancer KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first presentation of results from KEYNOTE-177, a Phase 3 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, for the first-line treatment of patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) unresectable or metastatic colorectal cancer. Language: English Contact: Media Contacts: Pamela Eisele (267) 305-3558 Justine Moore (908) 740-6449 Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 26, 2020
Merck Announces Third-Quarter 2020 Dividend
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company’s common stock for the second quarter of 2020. Payment will be made on July 7, 2020 to shareholders of record at the close of business on June 15, 2020. About Merck Language: English Contact: Media: Pamela Eisele (267) 305-3558 Investor: Peter Dannenbaum (908) 740-1037 Michael DeCarbo (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 26, 2020
Merck to Acquire Themis
Dateline City: KENILWORTH, N.J. Merck to Apply its Industry-Leading Vaccine Development Capabilities to SARS-CoV-2 Vaccine Program Originated by Themis and Institut Pasteur KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Themis, a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer, today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately-held Themis. Language: English Contact: Merck Media: Patrick Ryan +1 (201) 452-2409 Ian McConnell +1 (973) 901-5722 Themis Media & Investors Gretchen Schweitzer +49 172 861 8540 Jacob Verghese +49 89 2388 7731 Merck Investors: Peter Dannenbaum +1 (908) 740-1037 Michael DeCarbo +1 (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 20, 2020
LYNPARZA® (olaparib) Approved by FDA for Treatment of HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer That Has Progressed Following Prior Treatment with Enzalutamide or Abiraterone
Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone for Metastatic Castration-Resistant Prostate Cancer Patients with BRCA or ATM Mutations, A Key Secondary Endpoint in the Phase 3 PROfound Trial Approximately 20-30% of Men with Metastatic Castration-Resistant Prostate Cancer Have an HRR Gene Mutation KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Patients will be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA. Language: English Contact: Media Contacts: Pamela Eisele (267) 305-3558 Steve Wanczyk (267) 305-5563 Investor Contacts: Peter Dannenbaum (908) 740-1037 Courtney Ronaldo (908) 740-6132 Ticker Slug: Ticker: MRK Exchange: NYSE Organization,Facebook,Merck @Merck read more
May 19, 2020
Infectious Disease Connect and ILÚM Health Solutions Combine to Advance Precision Treatment of Infectious Diseases and Antimicrobial Stewardship
Dateline City: KENILWORTH, N.J. & PITTSBURGH Agreement Includes Strategic Investments from UPMC Enterprises and Merck Global Health Innovation Fund KENILWORTH, N.J. & PITTSBURGH--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and UPMC today announced that Infectious Disease Connect Inc., a UPMC-backed company offering telemedicine-enabled solutions to hospitals for treatment of infectious diseases, has combined with Merck’s ILÚM Health Solutions, a provider of technology and services to support infectious disease management, clinical decision-support and precision antibiotic therapy. Language: English Contact: UPMC Contact: Courtney Caprara Office: 412-647-6190 Mobile: 412-592-8134 E-mail: CapraraCL@upmc.edu UPMC Contact: Wendy Zellner Office: 412-586-9777 Mobile: 412-973-7266 Email: ZellnerWL@upmc.edu Merck Media Contact: Pamela Eisele 267-305-3558 Merck Investor Relations Contact: Peter Dannenbaum 908-740-1037 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
May 18, 2020
Merck Announces Appointment of Organon & Co. Chief Financial Officer and Chief Information Officer
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of Matthew Walsh and Rachel Stahler as Chief Financial Officer and Chief Information Officer, respectively, for Organon & Co., its intended spinoff of its women’s health, legacy brands and biosimilars businesses. Language: English Contact: Media: Jessica Fine (908) 740-1707 Kate Vossen (732) 675-8448 Investor: Peter Dannenbaum (908) 740-1037 Michael DeCarbo (908) 740-1807 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

You may also be interested in Related companies

logo
WinSanTor
HQ
San Diego, US
Employees
19 
WinSanTor is a biotechnology company focused on the discovery and development of treatments for peripheral neuropathies, including diabetic peripheral, chemo-induced peripheral, HIV-induced neuropathy, and others.
View company
logo
Amarillo Biosciences
HQ
Amarillo, US
Employees
2  -50decrease
Amarillo Biosciences (ABI) is a healthcare company that specializes in the development of novel biopharmaceuticals, medical treatments, and specialty consumer products.
View company
logo
TiumBio
HQ
Seongnam-si, KR
Employees
56 
TiumBio is a drug discovery company.
View company
logo
REMD Biotherapeutics
HQ
Camarillo, US
Employees
4 
REMD Biotherapeutics is a biopharmaceutical company focused on discovering and developing bio-medicines to treat cancer, diabetes, and other diseases.
View company
When was Merck founded?
Merck was founded in 1891.
Who are Merck key executives?
Merck's key executives are Robert Davis, Sanat Chattopadhyay and Dean Y. Li.
How many employees does Merck have?
Merck has 67,000 employees.
What is Merck revenue?
Latest Merck annual revenue is $48.7 b.
What is Merck revenue per employee?
Latest Merck revenue per employee is $726.93 k.
Who are Merck competitors?
Competitors of Merck include Trulieve, Bausch Health and Sanofi.
Where is Merck headquarters?
Merck headquarters is located at 2000 Galloping Hill Rd, Kenilworth.
Where are Merck offices?
Merck has offices in Kenilworth, Albuquerque, Alexandria, Allen and 235 other locations
How many offices does Merck have?
Merck has 247 offices.

Craft real-time company insights

Learn about Craft real-time company insights

Receive alerts for 300+ data fields across thousands of companies

Footer menu